4-Formyl-antipyrine, also known as 4-formyl-1,5-dimethyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one, is a chemical compound derived from antipyrine. Its synthesis involves the formylation of antipyrine, typically using a Vilsmeier-Haack reaction. 4-Formyl-antipyrine exhibits various pharmacological effects, including analgesic, anti-inflammatory, and antioxidant properties. It is known to inhibit the activity of certain enzymes, such as cyclooxygenase and lipoxygenase, contributing to its anti-inflammatory effects. Research on 4-Formyl-antipyrine is driven by its potential therapeutic applications in treating pain, inflammation, and oxidative stress-related diseases. Studies investigate its efficacy, mechanism of action, and potential side effects to explore its suitability for drug development.'
| ID Source | ID |
|---|---|
| PubMed CID | 70371 |
| CHEMBL ID | 1705468 |
| CHEBI ID | 177038 |
| SCHEMBL ID | 680008 |
| Synonym |
|---|
| EN300-27803 |
| CHEBI:177038 |
| 4-formyl-antipyrine |
| 1,5-dimethyl-3-oxo-2-phenylpyrazole-4-carbaldehyde |
| HMS2590M05 |
| MLS000720037 |
| 1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1h-pyrazole-4-carbaldehyde , |
| smr000304566 |
| nsc60408 |
| 950-81-2 |
| antipyraldehyde |
| 4-formylantipyrine |
| nsc-60408 |
| antipyrinaldehyd |
| antipyrine, 4-formyl- |
| 4-antipyrinecarboxaldehyde |
| 1h-pyrazole-4-carboxaldehyde,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl- |
| 4-antipyrinecarboxaldehyde, 97% |
| AKOS001482867 |
| STK895073 |
| NCGC00245823-01 |
| einecs 213-452-0 |
| 2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1h-pyrazole-4-carbaldehyde |
| nsc 60408 |
| 1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1h-pyrazole-4-carboxaldehyde |
| F0348-3312 |
| FT-0606970 |
| SCHEMBL680008 |
| [(1r,2s,5r)-2-isopropenyl-5-methyl-cyclohexyl] acetate |
| 1h-pyrazole-4-carboxaldehyde,2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl- |
| QFYZFYDOEJZMDX-UHFFFAOYSA-N |
| 2,3-dimethyl-5-oxo-1-phenyl-3-pyrazoline-4-carboxaldehyde |
| mfcd00003144 |
| J-640197 |
| 4-antipyrine carboxaldehyde |
| CHEMBL1705468 |
| PS-7929 |
| J-800198 |
| DTXSID10241720 |
| SR-01000078751-1 |
| sr-01000078751 |
| 4-formyl antipyrine |
| CS-0105020 |
| 4-antipyrinecarbaldehyde |
| Z247607354 |
| Q63398926 |
| 2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1h-pyrazole-4-carboxaldehyde |
| D94688 |
| SY081537 |
| Class | Description |
|---|---|
| pyrazoles | |
| ring assembly | Two or more cyclic systems (single rings or fused systems) which are directly joined to each other by double or single bonds are named ring assemblies when the number of such direct ring junctions is one less than the number of cyclic systems involved. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 89.1251 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| Glycoprotein hormones alpha chain | Homo sapiens (human) | Potency | 0.6310 | 4.4668 | 8.3448 | 10.0000 | AID624291 |
| Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 12.5893 | 1.9953 | 25.5327 | 50.1187 | AID624287 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| hormone activity | Glycoprotein hormones alpha chain | Homo sapiens (human) |
| protein binding | Glycoprotein hormones alpha chain | Homo sapiens (human) |
| follicle-stimulating hormone activity | Glycoprotein hormones alpha chain | Homo sapiens (human) |
| G protein activity | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| adenylate cyclase activator activity | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| extracellular region | Glycoprotein hormones alpha chain | Homo sapiens (human) |
| extracellular space | Glycoprotein hormones alpha chain | Homo sapiens (human) |
| Golgi lumen | Glycoprotein hormones alpha chain | Homo sapiens (human) |
| follicle-stimulating hormone complex | Glycoprotein hormones alpha chain | Homo sapiens (human) |
| pituitary gonadotropin complex | Glycoprotein hormones alpha chain | Homo sapiens (human) |
| extracellular space | Glycoprotein hormones alpha chain | Homo sapiens (human) |
| plasma membrane | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||